Search


Current filters:
Start a new search
Add filters:

Use filters to refine the search results.


Results 31-40 of 43 (Search time: 0.01 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
1999Comparison of (S)-mephenytoin and proguanil oxidation in vitro: contribution of several CYP isoforms.Coller, J.; Somogyi, A.; Bochner, F.
2005The influence of CYP2D6 genotype on trough plasma perhexiline and cis-OH-perhexiline concentrations following a standard loading regimen in patients with myocardial ischaemiaDavies, B.; Coller, J.; James, H.; Somogyi, A.; Horowitz, J.; Sallustio, B.
2011Measurement of Cyclosporine A in rat tissues and human kidney transplant biopsies - A method suitable for small (<1 mg) samplesNoll, B.; Coller, J.; Somogyi, A.; Morris, R.; Russ, G.; Hesselink, D.; van Gelder, T.; Sallustio, B.
2006Association between the DRD2 A(1) allele and response to methadone and buprenorphine maintenance treatmentsBarratt, D.; Coller, J.; Somogyi, A.
2007Lack of influence of CYP2D6 genotype on the clearance of (R)- (S)- and racemic-methadonColler, J.; Joergensen, C.; Foster, D.; James, H.; Gillis, D.; Christrup, L.; Somogyi, A.
2008TGFβ2 and TβRII are valid molecular biomarkers for the antiproliferative effects of tamoxifen and tamoxifen metabolites in breast cancer cellsBuck, M.; Coller, J.; Murdter, T.; Eichelbaum, M.; Knabbe, C.
2004Clinical inhibition of CYP2D6-catalysed metabolism by the antianginal agent perhexilineDavies, B.; Coller, J.; James, H.; Gillis, D.; Somogyi, A.; Horowitz, J.; Morris, R.; Sallustio, B.
2014Pharmacogenomics of methadone maintenance treatmentSomogyi, A.; Barratt, D.; Ali, R.; Coller, J.
2004Large interindividual variability in the in vitro formation of tamoxifen metabolites related to the development of genotoxicityColler, J.; Krebsfaenger, N.; Klein, K.; Wolbold, R.; Nussler, A.; Neuhaus, P.; Zanger, U.; Eichelbaum, M.; Murdter, T.
1999Flunitrazepam oxidative metabolism in human liver microsomes: involvement of CYP2C19 and CYP3A4Coller, J.; Somogyi, A.; Bochner, F.